A Study of CBX-12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer
Phase 2
40
about 1.1 years
18+
Female only
17 sites in AZ, CA, CT +10
What this study is about
This trial is testing a treatment called CBX-12 in women with ovarian cancer that has not responded to platinum chemotherapy. The goal is to see if this treatment is safe and effective.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take CBX-12
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Percentage of Subjects With Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)]
Secondary: Incidence of Subjects With Treatment Emergent Adverse Events (TEAEs), Median Duration of Response (DoR), Plasma levels of CBX-12 (Cmax), Plasma levels of CBX-12 (Tmax), Plasma levels of Exatecan (Cmax), Plasma levels of Exatecan (Tmax), Progression-Free Survival (PFS)
Oncology